Treatment of Refractory Cystoid Macular Edema with Pegylated Interferon Alfa-2A: A Retrospective Chart Review

被引：13
|
作者：
Stiefel, Hillary C. [1 ,2 ]
Kopplin, Laura J. [1 ,2 ,3 ]
Albini, Thomas [4 ]
Chang, Michael [1 ,5 ]
Vegunta, Sravanthi [4 ,6 ]
Suhler, Eric B. [1 ,2 ]
机构：
[1] Portland VA Hlth Care Syst, Dept Ophthalmol, Portland, OR USA
[2] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97201 USA
[3] Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA
[4] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA
[5] Oregon Hlth & Sci Univ, Hosp & Specialty Med, Portland, OR 97201 USA
[6] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA
来源：
OCULAR IMMUNOLOGY AND INFLAMMATION | 2021年 / 29卷 / 03期
基金：
美国国家卫生研究院;
关键词：
Pegylated interferon (peginterferon alfa-2A); uveitis; cystoid macular edema; CHRONIC HEPATITIS-C; UVEITIS; THERAPY; EFFICACY;
D O I：
10.1080/09273948.2019.1687729
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Purpose: To determine the efficacy of pegylated interferon alfa-2A in the treatment of refractory inflammatory cystoid macular edema (CME) Methods: Retrospective chart review Results: Treatment with pegylated interferon alfa-2A led to an improvement in CME in all eyes of seven included patients, with a mean decrease in CMT from 478 mu m to 310 mu m (p < .05). The vision in one patient did not improve due to preexisting retinal atrophy. All other eyes showed improvement in vision, with a mean improvement in best LogMAR visual acuity from +0.59 to +0.28 (p < .05). The treatment effect was sustained with low-dose treatment every 2 weeks or less in the majority of patients. Two patients who stopped interferon treatment given flu-like symptoms and intolerable rash, respectively, showed rapid recurrence of CME. Conclusions: Weekly administration of pegylated interferon alfa-2A is an effective treatment for refractory inflammatory CME, though side effects may limit tolerability in some patients.
引用
收藏
页码：566 / 571
页数：6
相关论文
共 50 条
  • [21] Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease
    Wechsler, B
    Bodaghi, B
    Huong, DLT
    Fardeau, C
    Amoura, Z
    Cassoux, N
    Piette, JC
    LeHoang, P
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2000, 8 (04) : 293 - 301
  • [22] Topical and Subcutaneous Interferon-Alpha for the Treatment of Refractory Inflammatory Macular Edema
    Green, Michael B.
    Butler, Nicholas J.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2024,
  • [23] Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
    Yacoub, Abdulraheem
    Mascarenhas, John
    Kosiorek, Heidi
    Prchal, Josef T.
    Berenzon, Dmitry
    Baer, Maria R.
    Ritchie, Ellen
    Silver, Richard T.
    Kessler, Craig
    Winton, Elliott
    Finazzi, Maria Chiara
    Rambaldi, Alessandro
    Vannucchi, Alessandro M.
    Leibowitz, David
    Rondelli, Damiano
    Arcasoy, Murat O.
    Catchatourian, Rosalind
    Vadakara, Joseph
    Rosti, Vittorio
    Hexner, Elizabeth
    Kremyanskaya, Marina
    Sandy, Lonette
    Tripodi, Joseph
    Najfeld, Vesna
    Farnoud, Noushin
    Papaemmanuil, Elli
    Salama, Mohamed
    Singer-Weinberg, Rona
    Rampal, Raajit
    Goldberg, Judith D.
    Barbui, Tiziano
    Mesa, Ruben
    Dueck, Amylou C.
    Hoffman, Ronald
    BLOOD, 2019, 134 (18) : 1498 - 1509
  • [24] Response to Pegylated Interferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 4
    El Makhzangy, Hesham
    Esmat, Gamal
    Said, Mohamed
    ElRaziky, Maissa
    Shouman, Soheir
    Refai, Rasha
    Rekacewicz, Claire
    Gad, Rita Raafat
    Vignier, Nicolas
    Abdel-Hamid, Mohamed
    Zalata, Khaled
    Bedossa, Pierre
    Pol, Stanislas
    Fontanet, Arnaud
    Mohamed, Mostafa K.
    JOURNAL OF MEDICAL VIROLOGY, 2009, 81 (09) : 1576 - 1583
  • [25] A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C
    Antonio Carrion, Jose
    Gonzalez-Colominas, Elena
    Garcia-Retortillo, Montserrat
    Canete, Nuria
    Cirera, Isabel
    Coll, Susanna
    Dolors Gimenez, Maria
    Marquez, Carmen
    Martin-Escudero, Victoria
    Castellvi, Pere
    Navines, Ricard
    Ramon Castano, Juan
    Anton Galeras, Josep
    Salas, Esther
    Bory, Felipe
    Martin-Santos, Rocio
    Sola, Ricard
    JOURNAL OF HEPATOLOGY, 2013, 59 (05) : 926 - 933
  • [26] Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera
    Gangaraju, Radhika
    Kim, Soo J.
    Dong, Jing-Fei
    Swierczek, Sabina
    Prchal, Josef T.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (06): : 757 - 760
  • [27] Ribavirin Impairs Salivary Gland Function in Hepatitis C Patients During Combination Treatment With Pegylated Interferon Alfa-2a
    Aghemo, Alessio
    Rumi, Maria Grazia
    Monico, Sara
    Banderali, Matteo
    Russo, Antonio
    Ottaviani, Francesco
    Vigano, Mauro
    D'Arnbrosio, Roberta
    Colombo, Massimo
    HEPATITIS MONTHLY, 2011, 11 (11) : 919 - 925
  • [28] Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review
    Sheppard, John D.
    CLINICAL OPHTHALMOLOGY, 2016, 10 : 2099 - 2111
  • [29] Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database
    Sato, Izumi
    Shimbo, Takuro
    Kawasaki, Yohei
    Masaki, Naohiko
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 283 - 289
  • [30] Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b
    Mach, Tomasz H.
    Ciesla, Andrzej
    Warunek, Wioleta
    Janas-Skulina, Urszula
    Cibor, Dorota
    Owczarek, Danuta
    Ciecko-Michalska, Irena
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2011, 121 (12): : 434 - 439
12345